Introduction
Aspreva is a pharmaceutical company involved in identifying, developing and commercializing drugs and drug candidates for the treatment of less common diseases. Aspreva has worldwide rights, excluding Japan, to develop and commercialize Roche's CellCept (mycophenolate mofetil) for all autoimmune indications.
Scope
Contains corporate strategy, value chain presence and SWOT Analysis
Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Report Highlights
Aspreva is focused on the development and commercialization of CellCept for autoimmune indications. The company develops CellCept for the indications such as Lupus nephritis, multiple sclerosis, pemphigus vulgaris, and scleroderma/systemic sclerosis. CellCept is under various stages of drug development process for the above said indications.
Aspreva derives its revenues from royalties received from its collaborative agreement with Roche. The company started recording revenues from fiscal 2005 only. Its total revenues increased from $76 million in 2005 and $215 million in 2006, representing an absolute total growth of +$139 million during 2005-2006.
The company is forecast to derive all of its revenues from CellCept royalties. The company's revenues are forecast to grow at a CAGR of 9% during 2006-2010, from $215 million to $304 million 2010. This represents an absolute growth of +$89 million.
Reasons to Purchase
Access all the important information and analysis on the company in a single report
Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain
Gain access to company's adjusted five year financial data along with key ratios and market capitalization
Report Highlights
[Studien Infos ausblenden]
